The POSH prospective cohort study showed no significant difference in overall survival or distant disease-free survival between patients carrying a BRCA1 or BRCA2 mutation and patients without these mutations after a diagnosis of breast cancer. This evidence concerns the gene BRCA1 and breast cancer.